• Clinical Insights: September 30, 2019

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.   New Drug Approval Jynneos™ (smallpox and monkeypox vaccine, live, nonreplicating) – New Vaccine Approval – September 24, 2019 – The U.S. Food and Drug Administration announced the approval… Read more »

  • 340B Insider – August 2019

                    Welcome to the August edition of RxStrategies’ 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view. Visit our website to read more.           RECAP: 340B COALITION SUMMER CONFERENCE It was great to connect with so many of our clients and industry leaders… Read more »

  • Stay on Top of 340B this Summer

    We are looking forward to connecting with you during the 340B Coalition Summer Conference being held July 15-17 in Washington, D.C. RxStrategies is proud to be a Pinnacle Sponsor for the event. Our team will be connecting with key leaders to discuss 340B comprehensive solutions, and share ideas on how to keep your 340B program on the right… Read more »

  • The Future of Policy at NACHC 2019

      March 27 – 30, RxStrategies representatives Rhodie Smith and Justin Rolling will attend the 2019 Policy and Issues Forum hosted by the National Association of Community Health Centers (NACHC). As one of the largest conferences on health policy, people from all corners of the administration and operations of health care will attend. The priorities… Read more »

  • Clinical Insights: October 10, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval TegsediTM (inotersen) – October 5, 2018 – Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc., announced that the U.S. Food and Drug… Read more »

  • Clinical Insights: August 30, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval AltrenoTM (tretinoin) – August 24, 2018 – Ortho Dermatologics, one of the largest prescription dermatology healthcare businesses in the world, announced that the U.S. Food and Drug… Read more »

  • Clinical Insights: August 3, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Mulpleta® (lusutrombopag) – July 31, 2018 – The Food and Drug Administration approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are… Read more »

  • 340B Insider – July 2018

    Welcome to the July edition of RxStrategies’ 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view.   UPDATES FROM THE 340B COALITION SUMMER CONFERENCE It was great to connect with so many of our clients and industry leaders during the 340B Coalition Summer Conference in Washington D.C. In addition to being a… Read more »